Press Releases

U.S. Patent No. 8,268,585 — “Transformation System In The Field of Filamentous Fungal Hosts”

JUPITER, Fla., September 24, 2012 – Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,268,585 entitled, “Transformation System in the Field ofFilamentous Fungal Hosts” by the United States Patent and Trademark Office (“USPTO”).

Dyadic’s President and CEO, Mark Emalfarb, stated, “We are very excited to have been granted this new U.S. patent containing such broad and encompassing claims that provide additional protection for the C1 fungal expression system for Dyadic, its customers and licensees.”

The inventions embodied by this patent describe methods of developing, programming and growing improved strains of the fungal microorganisms which make up Dyadic’s C1 platform technology. The patent claims cover the construction and use of C1 strains for the economical over-production of enzymes and other proteins at industrial scale for a broad number of applications such as food, animal feed, fuels and pharmaceuticals as well as primary and secondary metabolites such as organic acids and antibiotics.

Several of the issued patent claims relate to commercially advantageous properties of improved C1 strains which grow under low viscosity conditions and produce the targeted enzyme or other protein in a cleaner background which enhances the quality, quantity and cost-effectiveness of the final products. The patent also covers several molecular tools such as promoters and vectors which are integral to the process of gene expression resulting in higher productivity levels of enzymes and other proteins.

This patent is the eleventh U.S. patent issued to Dyadic adding to its portfolio of 58 international patents, 38 pending international and 13 pending U.S. patent applications which cover various features of Dyadic’s proprietary technologies.

The newly issued patent is accessible on the USPTO’s website or on Dyadic’s website at


Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.


Certain statements contained in this press release are forward- looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


Dyadic International, Inc.

Adam J. Morgan, Esq.

Vice President General Counsel & Business Development

Phone: 561-743-8333